PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: American International Biotechnology

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AIBioTech Announces Dr. Dave Li As Their New Clinical Director - American International Biotechnology, LLC (AIBioTech), Richmond VA, is proud to announce Dr. Dai (Dave) J. Li as their new Clinical Director - AIBioTech.com
AIBioTech Announces Dr. Dave Li As Their New Clinical Director

 

NewswireToday - /newswire/ - Richmond, VA, United States, 2015/03/19 - American International Biotechnology, LLC (AIBioTech), Richmond VA, is proud to announce Dr. Dai (Dave) J. Li as their new Clinical Director - AIBioTech.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dr. Li will be conducting clinical trial studies by utilizing the combined approach of diagnostic testing and clinical informatics in the field of precision medicine.
“I am excited about my new roles as the Clinical Director of AIBioTech. AIBioTech is at the forefront of the movement of precision medicine with its state-of-the-art assay portfolios and robust research capabilities especially that are enabled by the powerful Next Generation DNA Sequencing technologies for pharmacogenomics testing and cancer risk assessment. I have no doubt that the integrated approach of the innovative advanced laboratory testing with biomedical informatics as exemplified by the AIBioTech’s business model will provide greater insights of human illnesses propelling the future growth of the corporation and bring substantial value to the future patient care delivery and outcomes”, stated Dr. Li.

Dr. Li obtained his MB/MD at the Sun Yat-Sen University, School of Medicine and Cancer Center in Guangzhou, China, and his MSc/PhD from the University of Texas M.D. Anderson Cancer Center in Houston, Texas. He received additional training in tumor immunology from the Department of Surgery and Organ Transplantation at the University of Texas Health Science Center in Houston, as well as in Clinical Informatics from the Department of Health Informatics at The Johns Hopkins University School of Medicine in Baltimore, Maryland.

He completed a combined residency in medical oncology and laboratory medicine at the Sun Yat-Sen University Cancer Center in Guangzhou, China. Subsequently, he did clinical fellowships in Clinical Pathology at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital in Dallas, Texas, as well as at the Johns Hopkins Hospital in Baltimore, Maryland. Dr. Li’s career spans academic institutions, government and commercial operations including positions at Johns Hopkins Medical Institutions School of Medicine, Wako Chemicals, USA, Inc., the U.S. Food and Drug Administration, Wako Life Sciences and Health Diagnostic Laboratory, Inc.

Dr. Li is a physician certified by the American Medical Association (AMA) and the United States National Board of Medical Examiners holding a permanent ECFMG Certificate. He is also a certified clinical laboratory director by the College of American Pathologists (CAP) and Center for Medicare and Medicaid Services (CMS/CLIA). He is a member of many professional societies including AMA, American Society of Clinical Pathology (ASCP), American Society of Clinical Oncology (ASCO), and American College of Physician Executive (ACPE), American Medical Informatics Association (AMIA), and American Association for the Study of Liver Disease (AASLD), and Endocrine Society. Dr. Li has over twenty publications as an author or co-author in peer-reviewed medical journals, as well as book chapters on oncology drug discovery and development.

Dr. David Bostwick, CEO of AIBioTech, stated that “Dr. Li brings a great breadth of knowledge and experience to AIBioTech. His past work with the FDA, Johns Hopkins and HDL have given him a remarkably complete understanding of clinical needs in the current laboratory environment.”

About AIBioTech

AIBioTech (aibiotech.com) is a comprehensive contract research organization which provides clinical testing and research and development services to physicians and life science investigators in biotechnology and pharmaceutical companies, academic institutions, and in several different government agencies. It also operates a forensics and paternity testing division under the name Fairfax Identity Laboratories.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: American International Biotechnology

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AIBioTech Announces Dr. Dave Li As Their New Clinical Director

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Kelley W. Randall - AIBioTech.com 
804-648-3820 krandall[.]aibiotech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any American International Biotechnology securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From American International Biotechnology / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)